Amedica Releases First and Second Quarter 2017 Preliminary

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
109
Amedica Releases First and Second Quarter 2017 Preliminary Unaudited Earnings Report and Business Update

SALT LAKE CITY, UT--(Marketwired - Sep 22, 2017) - Amedica Corporation ( NASDAQ : AMDA ), a company that develops and commercializes silicon nitride for biomedical applications, today announced its preliminary earnings report for the first and second quarters ended March 31, 2017 and June 30, 2017, respectively, and provided a business update related to its business strategy and certain recent developments.

2017 Q1 PRELIMINARY EARNINGS REPORT -- UNAUDITED

Amedica reported preliminary unaudited revenue of $2.6 million for the first quarter of 2017 as compared to revenue of $4.2 million for the first quarter of 2016. Preliminary unaudited GAAP net loss for the first quarter of 2017 was $0.07 per share, compared to net loss of $0.30 per share in the first quarter of 2016. The company's cash and cash equivalents were $6.9 million at March 31, 2017, a decrease of $1.0 million from March 31, 2016.

2017 Q2 PRELIMINARY EARNINGS REPORT -- UNAUDITED

Amedica reported preliminary unaudited revenue of $3.2 million for the second quarter of 2017 and $5.8 million for the six month period ending June 30, 2017, as compared to revenue of $4.0 million for the second quarter of 2016 and $8.2 million for the six month period ending June 30, 2016. Preliminary unaudited GAAP net loss for the second quarter of 2017 was $0.05 per share, compared to net loss of $0.40 per share in the second quarter of 2016. For the six month period ended June 30, 2017, the company reported preliminary unaudited GAAP net loss of $0.12 per share, compared to a net loss of $0.71 per share in for the six month period ending June 30, 2016. The company's cash and cash equivalents were $3.5 million at June 30, 2017, a decrease of $1.7 million from June 30, 2016.

BUSINESS UPDATE AND RELATED DEVELOPMENTS

Unaudited Financial Update

As of September 1, 2017, the company has approximately $2.4 million of term debt payable to Hercules, down from $24.3 million of total debt owing in July 2015. The Hercules debt, being currently amortized, will retire by January 2018, or sooner. The company also has $2.7 million of debt payable to North Stadium Investments, without prepayment penalties, back-end fees, debt covenants, or other restrictions. The North Stadium Investments debt is currently being amortized and will retire by July 28, 2018, or sooner. 

Commercialization Report

The Alpha launch of Amedica's Taurus™ Pedicle Screw System, a spine fixation product line that received FDA clearance in November 2016, has now shifted to the Beta launch phase with the release of additional sets to the field. Over 125 new surgeries have been performed with the system generating over $750,000 in new revenue year-to-date. The company plans to release additional sets in the fourth quarter of 2017 to provide increased access to the system to meet new surgeon demand.

In August 2017, the company continued a trend of month-on-month increasing sales of the Taurus system and had its highest monthly revenue year to date. The August sales were led by high demand for the Taurus and Preference pedicle screw systems.  Other commercialization highlights include:

  • 38% increase in surgeons users since the end of 2016.
  • 14% increase in sales agents representing our products versus end of 2016, with many of these agents in parts of the United States that presently had no representation of the company's products.
  • A new Area Vice President for the Southeast region has been hired. His 20+ years of spine sales experience is consistent with the experience of other AVP and VP leadership team members.

Research and Development

Recent Research and Development Highlights:

  • During 2017, Amedica's R&D group has published 15 peer-reviewed journal articles and 7 scientific proceedings on various aspects of silicon nitride. 5 additional manuscripts are in preparation or are at various stages of submission and peer review.
  • There have been a total of 19 presentations made at scientific conferences to date. More recently, a presentation entitled, "Osteoinductive Properties of Silicon Nitride, Alumina, and Titanium," given at the ORS Midwest Musculoskeletal Workshop at Washington University Medical School in July won the "Best Poster" Award.
  • The company has completed an initial friction and wear test of polished silicon nitride against native cartilage. Preliminary data show that silicon nitride is at least non-inferior in its friction and wear performance as compared to typical cobalt chrome alloys that are currently used in this application.
  • Initial characterization and cell adhesion studies on silicon nitride, PEEK, and titanium performed under the company's multi-year agreement with Texas A&M University's School of Dentistry are consistent with prior independent studies showing favorable ionic, hydrophilic, and surface texture properties of silicon nitride.
  • Scientific data from the University of Rochester show resistance of silicon nitride to infection with Methicillin-Resistant Staphylococcal Aureus (MRSA), a major pathogen of concern in health care systems. These data, accepted for publication, are consistent with a number of internal and independent studies that have shown similar antimicrobial properties of silicon nitride against a variety of bacterial species, including those implicated in dental infections.

Clinical and Regulatory

As previously announced, in December 2016, Amedica re-filed an application with the FDA with a modified porous (cancellous structured ceramic) cervical implant. After a 510(k) pre-submission meeting, the company remains on track to file a 510k submission with a modified porous (cancellous structured ceramic) cervical implant in October 2017 based on FDA feedback.

In July 2017, Amedica's Quality Management System was audited by its notified body (BSI) and was certified to the ISO 13485:2016 standard.

Participation at Ladenburg Thalmann 2017 Healthcare Conference The Company also announced that Dr. Bal will make a presentation at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017, at 10:30 a.m. Eastern time in New York, NY.

A webcast of the presentation will be available during the presentation in the Investors section of the company's website at http://wsw.com/webcast/ladenburg3/amda/ , and will be archived and available at that site for 14 days.

Nasdaq Listing Status The company has received notice from The NASDAQ Stock Market LLC ("NASDAQ") indicating that a NASDAQ Hearings Panel (the "Panel") had granted the company's request to extend the stay of the suspension of trading in the company's common stock pending the company's scheduled hearing on October 12, 2017 before the Panel and a final determination regarding the company's listing status.

At the October 12, 2017 hearing, the company will present its plan to evidence compliance with NASDAQ's listing requirements. The company is diligently working to evidence compliance with NASDAQ's listing requirements as soon as possible; however, there can be no assurance that the Panel will grant the company's request for continued listing and a further stay of suspension. The delisting of the company's common stock from the NASDAQ Capital Market could have a material adverse effect on the company's business and on the trading of its common stock.

Strategic Direction

"Our focus at Amedica is three-fold. First, we are focused on product sales, i.e., increasing revenue so that the company is self-sustaining. Second, we will continue engagement with a number of major, external partners, developing biomedical applications of silicon nitride outside spinal implants. Third, we will continue to strengthen our leadership position in the science and data related to silicon nitride and its biomedical applications," said B. Sonny Bal, MD, MBA, JD, PhD; Chairman and CEO of Amedica.

Amedica continues to add new U.S surgeons to their customer base while remaining engaged with revenue opportunities in Brazil, Europe, and Australia, all markets where its silicon nitride implants are approved for commercialization.

About Amedica Corporation

Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company's products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com .

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements, which include statements regarding preliminary unaudited financial results, anticipated future revenues, FDA clearance of our products, addition of new surgeon users, and, results of clinical studies are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts: Amedica IR 801-839-3502 IR@amedica.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 249

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 231

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 432

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 211

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Elanco Secures FDA EUA for Credelio in Fighting NWS in Dogs

Updated Category News Views 275

Elanco's Innovative Step Against New World Screwworm Elanco Animal Health Incorporated (NYSE: ELAN) has achieved a significant milestone, receiving the first Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its product, Credelio™ (lotilaner), designed to treat infestations of New World Screwworm (NWS) in dogs. This groundbreaking...

Continue Reading
Hillary Ashton Sells Teradata Shares: Insights and Implications

Updated Category News Views 412

Hillary Ashton’s Sale of Teradata Shares: A Closer Look In an important insider transaction, Hillary Ashton, who is the Chief Product Officer at Teradata (TDC), recently sold 14,962 shares of the company's stock. This sale brought in a total of $411,903, as revealed in a recent SEC filing that highlights insider activity within the company. Currently, Teradata's stock...

Continue Reading
Legal Updates for Investors of Humana Inc. Amid Lawsuit

Updated Category News Views 158

Understanding the Ongoing Lawsuit Against Humana Inc. Investors focusing on the recent activities surrounding Humana Inc. (NYSE: HUM) should be aware of a significant lawsuit that has implications for individuals who acquired shares prior to July 2022. The Shareholders Foundation, Inc. has provided updates concerning the ongoing legal proceedings relevant to these...

Continue Reading
Empowering Local Job Seekers: The Trimborns of AtWork Tampa

Updated Category News Views 231

AtWork Opens New Storefront in Tampa, Florida AtWork, a prominent staffing franchise known for empowering job seekers and fostering company growth, has expanded its presence with a new location in Tampa. This strategic establishment at 8402 Laurel Fair Circle, Suite 101, stands across the Florida State Fairgrounds, ready to cater to the needs of the local workforce. Meet...

Continue Reading
Investor Claims Wall Street is Collapsing Cryptocurrency Values

Updated Category News Views 227

Investor Claims Wall Street is Collapsing Cryptocurrency Values Mike Alfred, a noted investor and proponent of Bitcoin, has raised significant concerns regarding potential manipulation of the cryptocurrency markets by major Wall Street players. He believes that these entities are actively working to drive down Bitcoin prices specifically to pressure companies like...

Continue Reading